The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed in this video are that co-existent fatty liver and related metabolic factors, including obesity and diabetes mellitus, exacerbate liver injury in patients with another chronic liver disease(s).
Video The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases -Copyright ©2023 by PanNash™ Initiative - All rights reserved.
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed in this video are that co-existent fatty liver and related metabolic factors, including obesity and diabetes mellitus, exacerbate liver injury in patients with another chronic liver disease(s). These may be risk factors for the development of more severe outcomes. The outlined findings have important therapeutic implications and indicate that fatty liver and the related metabolic factors should be taken into account even if they are not the primary cause of liver disease.
Would you like to read more?
Prof. Luisa Vonghia
Hepatic inflammatory responses in liver fibrosis
Recent technological advancements have provided unprecedented insights into the inflammatory mechanisms underlying liver fibrosis, leading to the identification of promising…
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause…
Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase…
Cardiovascular Disease in MASLD Patients: Mitigating Risks
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease…
Delving into the Latest Advancements in MASLD Treatment: Key Insights from Prof. Wong’s presentations at AASLD
Explore Prof. Wong's insights on MASLD treatment advancements from AASLD, featuring key drugs like Resmetirom, Lanifibranor, and Semaglutide with a…
Exploring the Promise of Pan-PPAR Agonism
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by…
Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases,…
Geographical burden of NAFLD: a review
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of…
Global research on fatty liver disease: a review
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden,…
Managing Hepatocellular Carcinoma in NAFLD: a review
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma…
The new paradigm of cardiometabolic syndrome: a review
Cardiometabolic syndrome (CMS) involves a complex interplay of many issues, involving obesity, metabolic dysregulation, cardiovascular disease, insulin resistance and more.…
Machine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
